Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

Bio-Rad Laboratories is viewed positively because its sales growth is expected to recover as idiosyncratic process-chromatography headwinds lapse in 2027, while Q3 showed its first organic growth quarter in 2026 at +0.7% and Clinical Diagnostics grew +2.8%. Management’s restructuring is also expected to lift margins, with $30–$35 million of net annualized cost savings reaffirmed and FY26 gross margin and operating margin guidance held at 53%-54% and 10%-12%. In addition, the company’s ~33% Sartorius stake provides meaningful longer-term optionality, even as its current valuation is kept at a discount to peers because growth remains challenged.

Bio-Rad Laboratories is facing a negative fundamental outlook because the market may assign a lower valuation if investors lose confidence in its sales and margin trajectory, while a further discount to the Sartorius stake could compound multiple erosion. The company also faces persistent operational and strategic risks, including prolonged end-market normalization in life science tools, ongoing ddPCR share losses to Qiagen over the past several years, and mixed M&A execution that could weaken growth and integration outcomes. Governance concerns add to the bearish case, as the Schwartz family’s control through the dual-class structure may limit shareholder influence, while AI-driven shifts away from wet-lab research could pressure the life sciences business structurally.